The Trust in Oncologist Scale (TiOS) was recently developed and validated in The Netherlands to assess cancer patients' trust in their oncologist. In this study, we translated and further validated the scale among English-speaking Australian cancer patients, to establish cross-cultural validity.
INTRODUCTION
Cancer patients are confronted with a life-threatening diagnosis and face difficult and lifealtering treatment decisions. Many patients experience distress, uncertainty and vulnerability [60] . A trusting relationship with the oncologist can alleviate patients' burden, increase involvement in decision making and reduce the inclination to request a second opinion [15, 17, 25, 87] . Hence, trust in the oncologist is important. However, since not much empirical research has shed light on why and how cancer patients trust their oncologist [138] , we know little about the realization, strength, predictors, and consequences of cancer patients' trust.
To gain a better understanding of patients' trust, one first needs to be able to assess it. The only instruments available to date were developed in the primary care setting [17, 61, 62] . The most recent of these, the Physician Trust Scale by Hall et al. [17] , has been validated most extensively [6] . However, this scale might not be fully applicable to cancer patients because of the specific nature of the oncology setting.
We therefore recently developed an oncology-specific trust measuring instrument in Dutch, the Trust in Oncologist Scale (TiOS), and established its reliability and validity among Dutch cancer patients [175] . The suitability of the TiOS for English-speaking cancer patients has not yet been confirmed. To allow for cross-cultural comparison, we validated an English translation of the TiOS among English-speaking Australian cancer patients. Dimensionality, construct validity, and reliability were assessed.
METHODS

Construction of the TiOS in Dutch
The TiOS was based on the ten-item Physician Trust Scale by Hall et al. [17] , and on qualitative data regarding cancer patients' explanations of trust [149] . A five-dimensional model of cancer patients' trust was constructed, encompassing Competence, Fidelity, Confidentiality, Honesty, and Caring. Appropriate items for all dimensions were collected from the Physician Trust Scale and related scales [17, 62, 86, 163] , or newly constructed. The resulting 33 candidate-items were pilot-tested. During questionnaire validation, the Confidentiality dimension was removed. The final 18-item scale comprised four dimensions, i.e., 1) Fidelity, the oncologist's pursuing the patients' interests, 2) Competence, the 104 oncologist's medical skills, 3) Honesty, telling the truth and avoiding intentional falsehoods, and 4) Caring, the oncologist's involvement, sympathy and devotion of attention to the patient. For a full description of the construction of the TiOS, see Hillen et al. [175] . The TiOS was translated into English following a forward-backward procedure [176] .
Validity testing
Patients and procedure
Adult, English-speaking cancer patients in treatment or follow-up were recruited from 
Analyses
For missing values, we used Expectation Maximization [170] . Using confirmatory factor analysis (CFA), we tested our four-dimensional model first, then a uni-dimensional representation of trust. A good model fit would be indicated by non-significant χ 2 , and
Root Mean Square Error of Approximation (RMSEA) <.06 [178] . As in the Dutch sample, we expected uni-dimensionality, but also a reasonably good fit of our four-dimensional model. We calculated internal consistencies (Cronbach's α), inter-item correlations and item-scale correlations for the TiOS. Construct validity was assessed by calculating Spearman's correlations between trust (TiOS) and its known correlates: satisfaction, trust in health care, and number of previous consultations with the oncologist. We expected that high trust levels would be strongly associated with high satisfaction, and moderately with strong trust in health care and a larger number of previous consultations [10, 17, 25, 44] . Exploratory, we assessed correlations between trust and patients' HRQOL, socio-demographics and disease characteristics. Analyses were performed using SPSS 16
[179], and Lisrel 8.5 [180] .
RESULTS
In total, 177 questionnaires were returned (response rate 70%, range 56-84% for the different locations). Data from two participants were excluded because of more than 25% missing data. Socio-demographic characteristics of the sample are shown in .62), willingness to recommend the oncologist to others (r s = .59), number of previous visits with the oncologist (r s = .21) and trust in health care (r s = .33). All correlations in the exploratory analyses were non-significant. Importantly, we found TiOS scores to be one-dimensional, indicating that these patients do not distinguish between different aspects of trust, i.e., Competence, Fidelity, Honesty, and Caring. Although this distinction was slightly stronger among Dutch patients, we still concluded that trust was best considered as a one-dimensional construct. The present findings confirm this suggestion of one-dimensionality. The even weaker distinction between dimensions of trust by Australian patients could reflect a more homogeneous composition of this sample. Even though mean trust was equally high in both samples, the Australian data lack sufficient variation in trust scores. Very few patients reported weak trust in their oncologist. This lack of variation may be due to Medical Ethical Committee regulations, prohibiting the random and direct approach of patients by mail as employed in the Dutch sample. Recruitment via the participating oncologists may have resulted in selection bias towards including only strongly trusting patients. Five-point Likert scale: totally disagree = 1, disagree = 2, as much agree as disagree = 3, agree = 4, strongly agree = 5.
Our repeated finding of one-dimensionality of patients' trust confirms earlier quantitative findings [17, 25, 62] . However, it contradicts qualitative findings suggesting that cancer patients do distinguish between dimensions of trust [13, 149] . This apparent discrepancy deserves further research attention. As yet, it appears difficult to quantitatively expose patients' possible distinction between trust dimensions. Further validation among specific groups of cancer patients with likely more varying levels of trust should be conducted, e.g., among second opinion patients, immigrants, or patients in palliative care, to investigate if the TiOS is responsive to more pronounced dimensionality and varying trust levels.
Conclusion
The current results contribute to research on cancer patients' trust in their oncologist.
Use of the TiOS allows further expansion of this field of study, resulting in better insight into the nature, predictors, and consequences of cancer patients' trust. Confidence in the cross-cultural validity of the TiOS enables its use in different countries, allowing direct comparisons between patients' trust levels internationally. Ultimately, this could contribute to improved patient care.
Practice implications
Our findings suggest that the English translation of the Trust in Oncologist Scale is suitable for use among English-speaking cancer patients in Australia and other countries with similarly organized health care systems. For the present, we suggest that when applying the TiOS, a single score can be used. However, for a more refined understanding of patients' trust, one might test whether patients in a specific sample distinguish different dimensions of trust.
